Nebula Research & Development LLC Sells 6,996 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Nebula Research & Development LLC reduced its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 21.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,020 shares of the company's stock after selling 6,996 shares during the period. Nebula Research & Development LLC's holdings in SpringWorks Therapeutics were worth $904,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in SWTX. Voya Investment Management LLC boosted its holdings in shares of SpringWorks Therapeutics by 9.3% in the 4th quarter. Voya Investment Management LLC now owns 796,684 shares of the company's stock valued at $28,784,000 after buying an additional 67,559 shares during the period. Syon Capital LLC acquired a new stake in SpringWorks Therapeutics during the 4th quarter valued at $490,000. Rock Springs Capital Management LP lifted its position in shares of SpringWorks Therapeutics by 64.6% in the fourth quarter. Rock Springs Capital Management LP now owns 328,911 shares of the company's stock worth $11,884,000 after purchasing an additional 129,056 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of SpringWorks Therapeutics by 132.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,931 shares of the company's stock valued at $323,000 after buying an additional 5,097 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of SpringWorks Therapeutics by 6.9% during the 4th quarter. MetLife Investment Management LLC now owns 42,089 shares of the company's stock worth $1,521,000 after purchasing an additional 2,702 shares during the last quarter.

Insiders Place Their Bets

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the transaction, the chief operating officer now directly owns 169,712 shares of the company's stock, valued at approximately $9,203,481.76. This trade represents a 10.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Saqib Islam sold 49,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $54.24, for a total value of $2,657,760.00. Following the sale, the chief executive officer now owns 954,869 shares of the company's stock, valued at $51,792,094.56. This represents a 4.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 440,766 shares of company stock valued at $24,402,956 over the last ninety days. 7.83% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

SWTX has been the topic of a number of research analyst reports. Barclays reaffirmed an "equal weight" rating and issued a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday. Cowen downgraded shares of SpringWorks Therapeutics to a "hold" rating in a research note on Tuesday. Guggenheim downgraded shares of SpringWorks Therapeutics from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $77.00 to $47.00 in a report on Monday. TD Cowen reiterated a "hold" rating and issued a $47.00 price objective (down from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday. Finally, Wedbush reaffirmed a "neutral" rating and issued a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, SpringWorks Therapeutics has an average rating of "Hold" and an average price target of $52.57.

SpringWorks Therapeutics Trading Up 0.0 %

SWTX stock traded up $0.02 during midday trading on Friday, hitting $46.23. The stock had a trading volume of 5,241,128 shares, compared to its average volume of 1,909,781. The business has a fifty day moving average price of $45.29 and a two-hundred day moving average price of $40.93. SpringWorks Therapeutics, Inc. has a 1-year low of $28.21 and a 1-year high of $62.00. The firm has a market cap of $3.47 billion, a P/E ratio of -13.28 and a beta of 0.79.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). The business had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. On average, equities analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.